Join
Live feed
·
PRReleasevia Quantisnow
Day One Biopharmaceuticals Inc. logo

Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

ByQuantisnow·Wall Street's wire, on your screen.
DAWN· Day One Biopharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DAWN (Day One Biopharmaceuticals Inc.) and more on Quantisnow.